Lack of Benefit of Intravenous Synthetic Human Secretin in the Treatment of Autism.
The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism. Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial. One group...
| Publicado en: | Journal of Autism & Developmental Disorders Vol. 32; no. 6; pp. 545 - 546 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | clinical trial research Journal Article |
| Publicado: |
Springer Nature
Dec2002
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106080159&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106080159 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01623257 AUT jtl: Journal of Autism & Developmental Disorders issn: 01623257 maglogo: N pubinfo: dt: Dec2002 vid: 32 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 106080159 106080159 2009390229 10.1023/a:1021202930206 NLM12553591 106080159 ppf: 545 ppct: 1 formats: fmt: @attributes: type: P tig: atl: Lack of Benefit of Intravenous Synthetic Human Secretin in the Treatment of Autism. aug: au: Molloy CA Manning-Courtney P Swayne S Bean J Brown JM Murray DS Kinsman AM Brasington M Ulrich CD II sug: subj: Autism Spectrum Disorder Drug Therapy Hormones, Synthetic Therapeutic Use Secretin Therapeutic Use Adolescence Child Child, Preschool Crossover Design Double-Blind Studies Female Human Injections, Intravenous Male Treatment Outcomes Adolescent: 13-18 years Child: 6-12 years Child, Preschool: 2-5 years Female Male ab: The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism. Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial. One group received 2 IU/kg of intravenous synthetic human secretin at the first visit, followed by an equal volume of intravenous saline placebo at week 6. The other group received treatments in the reverse order. All children were evaluated at weeks 1, 3, 6, 9, and 12 with standardized assessments of language, behavior, and autism symptomatology. There were no significant differences in the mean scores on any measure of language, behavior, or autism symptom severity after treatment with secretin compared to treatment with placebo. The results of this study do not support secretin as a treatment for autism. pubtype: Academic Journal doctype: clinical trial research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|